АМИНОПИЕЛИК® 600 СЛ
adama - Разтворим концентат (СЛ) - 600 г/л 2,4 Д аминна сол - Хербициди
ЕКЛИПС® 70 ВГ
adama - Вододиспергируеми гранули (ВГ) - 700 г/кг метрибузин - Хербициди
ЕФИКА® 960 ЕК
adama - Емулсионен концентрат (ЕК) - 960 г/л s-метолахлор - Хербициди
КАЛИФ® 360 КС
adama - Суспензия капсули (КС) - 360 г/л кломазон - Хербициди
СУЛКОТРЕК®
adama - Суспензионен концентат (СК) - 173 г/л сулкотрион + 327 г/л тербутилазин - Хербициди
ТРИМЕР® СХ
adama - Вододиспергируеми гранули (ВГ) - 500 г/кг трибенурон-метил - Хербициди
olumiant
eli lilly nederland b.v. - baricitinib - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant може да се използва като монотерапия или в комбинация с метотрексат. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
jetrea
inceptua ab - ocriplasmin - Ретинални заболявания - Офталмологични - jetrea е показан при възрастни за лечение на vitreomacular тяга (ВМТ), включително когато е свързан с макулна дупка с диаметър по-малко от или равно на 400 микрона.
semglee
viatris limited - инсулин гларжин - Захарен диабет - Лекарства, използвани при диабет - Лечение на захарен диабет при възрастни, юноши и деца на възраст над 2 години.